Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Catalent to Open Second Clinical Supply Facility in China

By Catalent Pharma Solutions | November 14, 2018

Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, plans to invest $2.5 million in a new, second clinical supply facility in Shanghai, China, due to open in early 2019. When completed, the facility is expected to employ 100 people and will double Catalent’s total clinical storage capacity in China.

The new 30,000 square-feet facility in Tangzhen, a district of Shanghai, will have three controlled temperature rooms operating at 2-8°C, 15-25°C, and -20°C, and will also offer returns and destruction services.

Its location, outside of the Free Trade Zone (FTZ), will provide clinical trial sponsors with increased speed and efficiency when running trials in China, and its proximity to Catalent’s existing FTZ facility in Waigaoqiao, within China’s Zhangjiang Pharma Valley, will allow the company to offer sponsors an optimized clinical supply solution for studies in both China and beyond.

Catalent will offer its FastChain demand-led supply services from the new facility, as well as from the existing FTZ site, affording sponsors access to in-country GMP secondary packaging, final assembly, labeling, and distribution of clinical supplies inside China, and in the wider Asia-Pacific region. FastChain demand-led supply services can reduce the time it takes for clinical sites to receive patient kits, and reduce waste from clinical trial material. 

The existing Waigaoqiao facility opened in 2013 and provides FTZ access, primary packaging, FastChain demand-led supply services, secondary packaging, clinical storage, and global distribution services.

(Source: Catalent Pharma Solutions)

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Prolific Machines logo.
Prolific Machines enters FDA program to enhance therapeutics manufacturing platform
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE